

19 December 2022

BSF Enterprise PLC

("BSF" or the "Company")

3D Bio-Tissues enters partnership with New Harvest

BSF (LSE:BSFA), an investment company focused on unlocking the next generation of biotech solutions and the development of lab-grown tissues, is pleased to announce that its 100% owned subsidiary, 3D Bio-Tissues Ltd ("3DBT"), has commenced a formal consulting collaboration with Stichting New Harvest Netherlands ("New Harvest"), a non-profit organisation dedicated to advancing cellular agriculture, focused on advancing 3DBT's route-to-market strategy and accelerating the commercialisation of its products worldwide.

New Harvest will provide 3DBT with a clear and comprehensive roadmap of the safety and regulatory requirements of animal-free media, its ingredients and derivatives in the European Union, UK, and others as time allows. The project is focused on aligning 3DBT's innovative City-mix™ cell-boosting supplements with existing international standards, including regulatory pathways for chemicals or substances added to food which have previously been deemed safe by experts.

The project, which will be undertaken over the next 12 months, will include:

- Expert analysis on the current regulatory and safety legislation relating to the manufacture and utilisation of animal-free media
- Predicted milestones and corresponding timeframes
- Defined action points

New Harvest is currently advancing understanding in the safety of cultivated meat and seafood research in partnership with various governments and intergovernmental organisations such as the Food and Agriculture Organization ("FAO") of the United Nations to drive forward a clear global framework for cultivated meat production with the overall aim of providing products to a growing market as well as significantly reducing greenhouse gas emissions from food production.

Che Connon, Chief Executive of 3D-Bio Tissues, said: *"Today's announcement marks the start of a significant workstream focused on putting affordable cultivated meat on shelves. New Harvest's partnerships across government and industry are integral to helping accelerate breakthroughs in cellular agriculture and laying the foundations for companies like 3DBT to drive the adoption of our products on a mass-scale. We look forward to working with them as we continue to unveil further larger-scale prototypes and the UK's first lab-grown fillet in the coming months."*

Isha Datar, Executive Director of New Harvest, said: *"Bringing together the public and private sectors to advance cellular agriculture is critical to our collective mission and success. We are delighted to be working with the team at 3DBT on bringing more real-world understanding and information on the safety and regulatory aspects of cell cultured meat and seafood to the public. Their product and their collaborative approach will be of benefit to the entire field at large."*

For further enquiries, please visit www.bsfenterprise.com or contact:

BSF Enterprise PLC	Via SEC Newgate below
Geoff Baker - Non-Executive Director Che Connon - Executive Director	
Shard Capital (Broker)	
Damon Heath	0203 971 7000
SEC Newgate (Financial Communications)	
Bob Huxford Elisabeth Cowell	020 3757 6882 BSF@secnewgate.co.uk

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultivated meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio Tissues Ltd (3DBT), a tissue engineering company with patent-protected IP that is already producing human corneas that will help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality lab-grown meat from its laboratory in Newcastle the next 12 months, transforming the meat-production industry towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.